OmniAb, Inc. (OABI)

About OmniAb, Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

As of November 3, 2026, OmniAb, Inc. (OABI) stock edged higher to $5.11, up 0.29% (+$0.01) versus the previous close. On the day, shares have traded between $5.02 and $5.37. That puts OABI near the top of its 52-week range of $1.30 to $5.43. OmniAb, Inc. operates in the services-commercial physical & biological research space and carries a market capitalization of roughly $745.35 million, with about 944.5K shares changing hands.

Latest OABI news

• OmniAb (OABI) Q3 Results Keep Cash Progress In FocusYahoo Finance· Nov 1, 4:11 AM ET
• OmniAb, Inc. Q3 2026 Earnings Call Summaryapp.moby.co· Oct 30, 5:03 PM ET
• OmniAb (OABI) Q3 2026 Earnings Call Transcriptfool.com· Oct 30, 2:58 PM ET
• OmniAb Q3 Earnings Call Highlightsmarketbeat.com· Oct 30, 11:14 AM ET
• OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· Oct 30, 7:50 AM ET
• OmniAb Reports Third Quarter 2026 Financial Results and Business HighlightsYahoo Finance· Oct 30, 7:40 AM ET
• OmniAb to Participate in Upcoming Investor Conferences in NovemberYahoo Finance· Oct 26, 4:05 PM ET
• OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conferencemarketbeat.com· Oct 25, 12:02 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want OABI headlines, alerts and AI research in one place? Create a free account →

• $OABI As OABI grows into more of a royalty driven company earnings should really take off. Silly why so many sold after the earnings call Nice recovery at the close Lots of potential here

  @bearsoil· Oct 30, 7:38 PM ET

• $OABI Not a bad close ! Not bad

  @Posna· Oct 30, 3:48 PM ET

• $OABI reported before the open this morning. GAAP EPS of -$0.12 beat the -$0.13 analyst estimate by 5.6%, according to Stock Meadow. Revenue was $3.99M versus $3.49M expected.

  @shoc24· Oct 30, 2:15 PM ET· Bullish

• https://www.marketbeat.com/earnings/reports/2026-10-30-omniab-inc-stock/ $OABI OmniAb Earnings Transcript

  @EarningsInsider· Oct 30, 9:01 AM ET

• $OABI its fate is completely tied to success or failure of its partners. It will probably not dilute for another 6 months or so. If JNJ-79635322 gives it a milestone payment in the meantime, it may not need to dilute at all. The organic company revenues are tiny and irrelevant…

  @HypnoTrader· Oct 30, 8:51 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →